KIORA PHARMACEUTICALS, INC. Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option
KIORA PHARMACEUTICALS, INC. (KPRX) reported Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes
us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2021-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2021-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2021-06-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for the quarter ending 2021-03-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for fiscal 2025 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for fiscal 2024 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for fiscal 2023 was $0.00.
- KIORA PHARMACEUTICALS, INC. increase (decrease) in fair value adjustments on other assets (liabilities) carried at fair value under fair value option for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 3 month | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 6 month | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 9 month | Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-25 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-25 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-25 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $0.00 10-K/A · filed 2022-07-07 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |